Dare Bioscience, Inc.
DARE · XNASCIK 1401914fmd_07P4T13QTC4S707PQJXMB7HQFEManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2012 to Jun 30, 2026, 55 periods
Latest annual · FY2025
Millions- Total revenues
- 1
- Gross profit
- 1
- Operating income
- (14)
- Net income
- (13)
- Free cash flow
- (10)
Latest quarter · Q2 FY2026
Millions- Total revenues
- 0
- Gross profit
- (0)
- Operating income
- (3)
- Net income
- (3)
- Free cash flow
- (7)
Daily close · DAREIEX trades only
Oct 21, 2025 to Nov 11, 2026 · 250 sessions0.70 USD
Built from trades executed at IEX only, one exchange with a small share of US volume. This is not the consolidated tape. The close is the last IEX trade of the session, not the official closing price. Earlier sessions are divided by the later split ratios the API confirmed against IEX prices; dividends are not adjusted. Switch to As traded for the prices as they printed. End of day, not real time: a session is published the day after it trades.
Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use. iex.io/legal/hist-data-terms
Key stats
Open AnalysisCompound annual growth
- Revenue, 3 yearsFY2022 to FY2025
- -53.1%
- Revenue, 5 yearsFY2020 to FY2025
- n/m
- Net income, 5 yearsFY2020 to FY2025
- n/m
Dare Bioscience, Inc. (DARE) financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2025 | FY2024 | Change | Source |
|---|---|---|---|---|
| Revenue | $1 million | $9,784 | +10,429.4% | 10-K 2026-03-26 · proof |
| Gross profit | $734,394 | $9,784 | +7,406.1% | 10-K 2026-03-26 · proof |
| Operating income | -$13.6 million | -$23.5 million | 10-K 2026-03-26 · proof | |
| Net income | -$13.4 million | -$4.1 million | 10-K 2026-03-26 · proof | |
| Cash from operating activities | -$9.9 million | $5.5 million | -280.6% | 10-K 2026-03-26 · proof |
| Free cash flow | -$10.3 million | $4.9 million | -309.6% | 10-K 2026-03-26 · proof |
| Total assets | $32.5 million | $22.1 million | +46.9% | 10-K 2026-03-26 · proof |
| Total liabilities | $29.6 million | $28.1 million | +5.4% | 10-K 2026-03-26 · proof |
| Cash and cash equivalents | $24.7 million | $15.7 million | +57.4% | 10-K 2026-03-26 · proof |
- What was Dare Bioscience, Inc. (DARE)'s revenue in fiscal 2025?
- Dare Bioscience, Inc. (DARE) reported revenue of $1 million for fiscal 2025 (the year ended Dec 31, 2025), against $9,784 the year before (+10,429.4%). Source: the 10-K filed with the SEC on Mar 26, 2026. SEC
- What was Dare Bioscience, Inc. (DARE)'s gross profit in fiscal 2025?
- Dare Bioscience, Inc. (DARE) reported gross profit of $734,394 for fiscal 2025 (the year ended Dec 31, 2025), against $9,784 the year before (+7,406.1%). Source: the 10-K filed with the SEC on Mar 26, 2026. SEC
- What was Dare Bioscience, Inc. (DARE)'s operating income in fiscal 2025?
- Dare Bioscience, Inc. (DARE) reported operating income of -$13.6 million for fiscal 2025 (the year ended Dec 31, 2025), against -$23.5 million the year before. Source: the 10-K filed with the SEC on Mar 26, 2026. SEC
- What was Dare Bioscience, Inc. (DARE)'s net income in fiscal 2025?
- Dare Bioscience, Inc. (DARE) reported net income of -$13.4 million for fiscal 2025 (the year ended Dec 31, 2025), against -$4.1 million the year before. Source: the 10-K filed with the SEC on Mar 26, 2026. SEC
- What was Dare Bioscience, Inc. (DARE)'s cash from operating activities in fiscal 2025?
- Dare Bioscience, Inc. (DARE) reported cash from operating activities of -$9.9 million for fiscal 2025 (the year ended Dec 31, 2025), against $5.5 million the year before (-280.6%). Source: the 10-K filed with the SEC on Mar 26, 2026. SEC
- What was Dare Bioscience, Inc. (DARE)'s free cash flow in fiscal 2025?
- Dare Bioscience, Inc. (DARE) reported free cash flow of -$10.3 million for fiscal 2025 (the year ended Dec 31, 2025), against $4.9 million the year before (-309.6%). Source: the 10-K filed with the SEC on Mar 26, 2026. SEC
- What are Dare Bioscience, Inc. (DARE)'s total assets?
- As of Dec 31, 2025, Dare Bioscience, Inc. (DARE) reported total assets of $32.5 million, against $22.1 million a year earlier (+46.9%). Source: the 10-K filed with the SEC on Mar 26, 2026. SEC
- What are Dare Bioscience, Inc. (DARE)'s total liabilities?
- As of Dec 31, 2025, Dare Bioscience, Inc. (DARE) reported total liabilities of $29.6 million, against $28.1 million a year earlier (+5.4%). Source: the 10-K filed with the SEC on Mar 26, 2026. SEC
- What are Dare Bioscience, Inc. (DARE)'s cash and cash equivalents?
- As of Dec 31, 2025, Dare Bioscience, Inc. (DARE) reported cash and cash equivalents of $24.7 million, against $15.7 million a year earlier (+57.4%). Source: the 10-K filed with the SEC on Mar 26, 2026. SEC
Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=ticker:DARE&period_type=annual&limit=5"Information only, not investment advice.